Actively Recruiting
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Led by University of Washington · Updated on 2026-03-04
27
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
Sponsors
U
University of Washington
Lead Sponsor
S
Swedish Orphan Biovitrum
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic stem cell transplantation (bridging) for patients with accelerated and blast phase myeloproliferative neoplasms. Pacritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine and decitabine are in a class of medications called hypomethylation agents. They work by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Adding pacritinib to standard of care azacitidine or decitabine may increase the number of patients able to proceed to hematopoietic stem cell transplantation for patients with accelerated and blast phase myeloproliferative neoplasms.
CONDITIONS
Official Title
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- History of myeloproliferative neoplasms with at least 5% blasts in bone marrow or peripheral blood
- Confirmed diagnosis by WHO criteria including related syndromes
- ECOG performance status 0 to 2 or Karnofsky score 60% or higher
- Serum creatinine clearance of at least 50 ml/min within 14 days before treatment
- Total bilirubin 3 or less (higher allowed if due to specific conditions) within 14 days before treatment
- AST and ALT less than 3 times the upper limit of normal within 14 days before treatment
- Considered a potential transplant candidate as determined by physician
- Plan to begin hypomethylating agent therapy with azacitidine or decitabine per institutional standards
- May have been treated with leukapheresis or up to 2 doses of cytarabine prior to enrollment if needed
- Women of childbearing potential and men must agree to use effective contraception during and 90 days after treatment
- Able to provide informed consent
You will not qualify if you...
- Prior chemotherapy treatment for myeloproliferative neoplasm, except the first allowed cycle of hypomethylating agent within 30 days
- Active systemic infection not controlled or stable
- Known allergy to any study drug
- Pregnant or breastfeeding women (negative pregnancy test required for women of childbearing potential)
- Use of other investigational agents for MDS/leukemia within 2 weeks before study start
- Corrected QT interval greater than 480 msec not improved by medication or electrolyte changes
- Use of strong CYP3A4 inhibitors or inducers that cannot be stopped before study enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
A
Anna Halpern, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here